After announcing earlier this week the appointment of Andreas Wallnöfer, PhD, MBA, to its Board of Directors, Optigo ...
Opus Genetics has completed a Type B Regenerative Medicine Advanced Therapy (RMAT) meeting with the US Food and Drug ...
The company describes KSI-101 as a “novel, potent, and high-strength (100 mg/mL) antibody-based investigational therapy with ...
An expert demonstrates how to safely co-manage AMD and GA using staggered dual-pathway treatment to maintain stability and ...
An expert summarizes real-world GA management lessons, highlighting personalized imaging-guided care and patient-centered ...
PolyActiva and RareSight collaborate to create innovative therapies for rare pediatric retinal diseases, aiming to transform ...
An expert outlines vision-preserving strategies for monocular high-risk GA, emphasizing early intervention and tailored ...
In this inaugural episode of the Ophthalmology Times ® “Beyond The Walls” podcast, host Deborah Ristvedt, DO, of Vance ...
Dr. Andreas Wallnöfer joins Optigo Biotherapeutics' Board, bringing expertise from Jeito Capital, BioMedPartners, and Roche.
4D Molecular Therapeutics (4DMT) released positive interim 1.5- to 3.5-year data from the phase 1/2 PRISM clinical trial ...
Avisi Technologies has released positive 12-month clinical data on the VisiPlate Aqueous Shunt from the VITA Trial. The VITA ...
Topline results that were recently released from Sydnexis’s phase 3 Study of Atropine for the Reduction of Myopia Progression ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback